Adoptive cell therapy (ACT) uses cancer reactive T-cells to effectively treat cancer patients. Producing many persistent T-cells is critical for successful treatments. Researchers at the National Cancer Institute (NCI) have developed a method of producing larger populations of minimally-differentiated T-cells. NCI seeks licensing and/or co-development research collaborations to further develop, evaluate, and/or commercialize this novel method of producing effective T-cell populations using p38 mitogen-activated protein kinase (MAPK) inhibitors.
Pluripotent stem cells are a promising source of T cells for a variety of clinical applications. However, current in vitro methods of T cell differentiation result in the generation of cells with aberrant phenotypes. Researchers at the National Cancer Institute (NCI) have now developed methodology for generating induced pluripotent stem cell thymic emigrants (iTE). Antigen-specific CD8αβ+ iTEs exhibited functional properties in vitro that were almost indistinguishable from natural naïve CD8αβ+ T cells, including vigorous expansion and robust anti-tumor activity. iTEs recapitulated many of the transcriptional programs of naïve T cells in vivo and revealed a striking capacity for engraftment, memory formation, and efficient tumor destruction. The NCI seeks licensing and/or co-development research collaborations for this invention.
Antibodies that specifically recognize and bind to the unshed portion (“stalk”) of human mesothelin are strong therapeutic candidates because they maintain contact with the cancer cell for a longer duration than other anti-mesothelin antibodies that are currently available. The National Cancer Institute (NCI) has developed such antibodies that specifically recognize and bind to the stalk of human mesothelin with high affinity. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these antibodies.
The National Institutes of Health Clinical Center (NIH CC) and the National Cancer Institute (NCI) are seeking parties interested in licensing a multi-foci sonication approach combined with a mild hyperthermia heating algorithm and implemented on a clinical Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MR-HIFU) platform.
The promise of RNA interference based therapeutics is made evident by the recent surge of biotechnological drug companies that pursue such therapies and their progression into human clinical trials. The present technology discloses novel RNA and RNA/DNA nanoparticles including multiple siRNAs, RNA aptamers, fluorescent dyes, and proteins. The National Cancer Institute sees parties interested licensing this technology or in collaborative research to co-develop RNAi-based nanoparticle therapeutics for cancer and HIV.
The National Cancer Institute (NCI) seeks research a co-development partner and/or licensees for applications utilizing the nanoparticle platform technology for delivery of cancer-specific microRNAs, particularly for therapeutic uses in surface cancers, such as mesothelioma.
The National Cancer Institute seeks partners interested in licensing or collaborative research to co-develop a treatment for Ewing's Sarcoma, with a goal of preclinical evaluation leading to clinical testing.
Researchers at the National Cancer Institute (NCI) developed novel groups of cyanine (Cy) based antibody-drug conjugate (ADC) chemical linkers that undergo photolytic cleavage upon irradiation with near-IR light. By using the fluorescent properties of the Cy linker to monitor localization of the ADC, and subsequent near-IR irradiation of cancerous tissue, drug release could be confined to the tumor microenvironment.
Researchers at the National Cancer Institute (NCI) have developed a new format for expressing Chimeric Antigen Receptors (CARs) that is available for licensing and co-development. The inventors found that there was an increased therapeutic effect when using their proprietary (anti-glypican 3 [GPC3]) hYP7 antibody in this format. The novel technology is useful for improving CAR therapies to treat a range of cancers.
Inventors at the National Cancer Institute (NCI) developed novel recombinant immunotoxins (RITs) with a long half-life due to added albumin binding domains (ABD) and high anti-tumor activity. This technology is available for research co-development partnering or licensing.
Researchers at the NCI have developed a novel treatment for adrenocortical cancer (ACC) by repositioning the drug niclosamide. New treatments for ACC can help patients with this rare and aggressive disease, where the current standard of care involves highly toxic options. The NCI seeks parties to license this method of treating adrenocortical cancer using niclosamide.
Metastatic thyroid cancer can be resistant to current treatment options such as radioactive iodine therapy. Targeting thyroglobulin, a thyroid-specific antigen, as part of an adoptive cell therapy approach will allow for new therapeutic possibilities. Researchers at the National Cancer Institute (NCI) seek licensing and/or co-development research collaborations for novel T-cell receptors for the treatment of metastatic thyroid cancer.
Cancer cells have been found to directly activate resting B cells to form suppressive regulatory B cells (tBregs) and utilize them to evade immune surveillance and mediate metastasis. tBregs directly inhibit CD4+ and CD8+ T cell activity in a cell contact-dependent manner, induce FoxP3+ T cell activity, and promote Treg-dependent metastasis. The National Institute on Aging's Immunotherapeutics Unit, is seeking parties interested in licensing or co-development of regulatory B cells to control autoimmune diseases and strategies that inactivate tBregs to control cancer immune escape.
RNA interference (RNAi) is a naturally occurring cellular post-transcriptional gene regulation process that utilizes small double-stranded RNAs to trigger and guide gene silencing. By introducing synthetic RNA duplexes called small-interfering RNAs (siRNAs), we can harness the RNAi machinery for therapeutic gene control and the treatment of various diseases. The National Cancer Institute seeks partners to license or co-develop RNA, RNA-DNA, and DNA-RNA hybrid nanoparticles consisting of a DNA or RNA core with attached RNA or DNA hybrid duplexes.
Researchers at the National Cancer Institute (NCI) have developed a method to epigenetically reprogram CD8+ T cell fate by expressing elevated levels of the polycomb-like protein, Phf19. This technology is useful for improving T cell-based immunotherapies (such as CAR therapies) to treat a range of infectious diseases and cancers. NCI seeks licensing or co-development partners for this invention.